Home » Stocks » MREO

Mereo BioPharma Group PLC (MREO)

Stock Price: $2.36 USD -0.11 (-4.45%)
Updated Oct 28, 2020 12:50 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 159.29M
Revenue (ttm) n/a
Net Income (ttm) -34.84M
Shares Out 67.50M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $2.36
Previous Close $2.47
Change ($) -0.11
Change (%) -4.45%
Day's Open 2.36
Day's Range 2.26 - 2.47
Day's Volume 49,661
52-Week Range 0.69 - 4.25

More Stats

Market Cap 159.29M
Enterprise Value 180.43M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 67.50M
Float 58.80M
EPS (basic) n/a
EPS (diluted) -2.05
FCF / Share -3.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 946,330
Short Ratio 6.26
Short % of Float 1.61%
Beta 1.03
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.52
Revenue n/a
Operating Income -52.00M
Net Income -34.84M
Free Cash Flow -60.46M
Net Cash -21.14M
Net Cash / Share -0.32
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -20.81%
ROE -344.02%
ROIC -174.60%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $2.36
Target: 8.00
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions GBP.

Financial Overview

Operating Income-39.52-34.48-45.30-36.18
Net Income-34.84-32.03-38.80-28.39
Shares Outstanding71.2486.9986.9986.99
Earnings Per Share-1.56-1.80-2.24-2.52
Operating Cash Flow-45.93-23.14-32.15-29.66
Capital Expenditures-0.02-0.03-0.02-
Free Cash Flow-45.95-23.17-32.17-29.66
Cash & Equivalents16.3527.5452.5453.58
Total Debt32.4221.4920.75-
Net Cash / Debt-16.076.0631.7953.58
Book Value40.2632.7762.4879.26
Numbers in millions GBP, except per-share numbers.

Company Profile

Company Details

Full Name Mereo BioPharma Group PLC
Country United Kingdom
Employees 50
CEO Denise Vera Scots-Knight

Stock Information

Ticker Symbol MREO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MREO


Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.